Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
ABSTRACT Purpose The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) remains understudied, with limited long‐term data from large cohorts inclusive of both salvage radiotherapy (SRT)‐treated and untreated patients. Herein, we sought to evaluate the outcomes of patien...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70988 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849413343070126080 |
|---|---|
| author | Spyridon P. Basourakos Stephen A. Boorjian Phillip J. Schulte Grant Henning Jamie T. O'Byrne Matthew K. Tollefson Igor Frank Abhinav Khanna Ryan M. Phillips Bradley J. Stish R. Jeffrey Karnes Vidit Sharma |
| author_facet | Spyridon P. Basourakos Stephen A. Boorjian Phillip J. Schulte Grant Henning Jamie T. O'Byrne Matthew K. Tollefson Igor Frank Abhinav Khanna Ryan M. Phillips Bradley J. Stish R. Jeffrey Karnes Vidit Sharma |
| author_sort | Spyridon P. Basourakos |
| collection | DOAJ |
| description | ABSTRACT Purpose The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) remains understudied, with limited long‐term data from large cohorts inclusive of both salvage radiotherapy (SRT)‐treated and untreated patients. Herein, we sought to evaluate the outcomes of patients with BCR and the impact of SRT on disease progression. Materials and Methods Patients undergoing RP who developed BCR (PSA ≥ 0.20 ng/mL) were included. Patients with BCR treated with SRT were compared to untreated patients using risk‐set matching with time‐dependent propensity scores. The primary outcome was metastases, analyzed using Kaplan–Meier and Cox models. The number needed to treat (NNT) with SRT to prevent progression was derived at 5 and 15 years. Results Among 6881 patients with BCR, 2109 received SRT. At a median follow‐up of 10.2 years, 1147 patients developed metastases. The median PSA at the time of SRT was 0.50 ng/mL. After 1:1 propensity score matching (2109 patients per cohort), SRT significantly reduced the risk of metastases at 5 (12.7% vs. 19.3%, p < 0.0001) and 15 years (28.6% vs. 31.5%, p < 0.001). On multivariable analysis, SRT independently reduced metastasis risk (HR 0.75, 95% CI 0.63–0.90, p = 0.002), translating to NNT of 23 and 15 at 5 and 15 years, respectively. Interaction analyses between SRT and nodal status (p = 0.04) showed greater metastasis risk reduction in pN+ (HR 0.41, 95% CI 0.22–0.77, p = 0.005) compared to pN− disease (HR 0.81, 95% CI 0.67–0.97, p = 0.02). Conclusions Most patients with BCR post‐RP do not progress to metastasis. For those who do progress, SRT inarguably improves the oncologic outcomes in the BCR setting. However, careful patient selection and shared decision making should be encouraged in order to limit overtreatment and side effects. |
| format | Article |
| id | doaj-art-60c4e562cbda48888e47639a04663144 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-60c4e562cbda48888e47639a046631442025-08-20T03:34:09ZengWileyCancer Medicine2045-76342025-07-011413n/an/a10.1002/cam4.70988Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical ProstatectomySpyridon P. Basourakos0Stephen A. Boorjian1Phillip J. Schulte2Grant Henning3Jamie T. O'Byrne4Matthew K. Tollefson5Igor Frank6Abhinav Khanna7Ryan M. Phillips8Bradley J. Stish9R. Jeffrey Karnes10Vidit Sharma11Department of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Health Sciences Research Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Health Sciences Research Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Radiation Oncology Mayo Clinic Rochester Minnesota USADepartment of Radiation Oncology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USADepartment of Urology Mayo Clinic Rochester Minnesota USAABSTRACT Purpose The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) remains understudied, with limited long‐term data from large cohorts inclusive of both salvage radiotherapy (SRT)‐treated and untreated patients. Herein, we sought to evaluate the outcomes of patients with BCR and the impact of SRT on disease progression. Materials and Methods Patients undergoing RP who developed BCR (PSA ≥ 0.20 ng/mL) were included. Patients with BCR treated with SRT were compared to untreated patients using risk‐set matching with time‐dependent propensity scores. The primary outcome was metastases, analyzed using Kaplan–Meier and Cox models. The number needed to treat (NNT) with SRT to prevent progression was derived at 5 and 15 years. Results Among 6881 patients with BCR, 2109 received SRT. At a median follow‐up of 10.2 years, 1147 patients developed metastases. The median PSA at the time of SRT was 0.50 ng/mL. After 1:1 propensity score matching (2109 patients per cohort), SRT significantly reduced the risk of metastases at 5 (12.7% vs. 19.3%, p < 0.0001) and 15 years (28.6% vs. 31.5%, p < 0.001). On multivariable analysis, SRT independently reduced metastasis risk (HR 0.75, 95% CI 0.63–0.90, p = 0.002), translating to NNT of 23 and 15 at 5 and 15 years, respectively. Interaction analyses between SRT and nodal status (p = 0.04) showed greater metastasis risk reduction in pN+ (HR 0.41, 95% CI 0.22–0.77, p = 0.005) compared to pN− disease (HR 0.81, 95% CI 0.67–0.97, p = 0.02). Conclusions Most patients with BCR post‐RP do not progress to metastasis. For those who do progress, SRT inarguably improves the oncologic outcomes in the BCR setting. However, careful patient selection and shared decision making should be encouraged in order to limit overtreatment and side effects.https://doi.org/10.1002/cam4.70988biochemical recurrenceprostate cancersalvage radiation therapy |
| spellingShingle | Spyridon P. Basourakos Stephen A. Boorjian Phillip J. Schulte Grant Henning Jamie T. O'Byrne Matthew K. Tollefson Igor Frank Abhinav Khanna Ryan M. Phillips Bradley J. Stish R. Jeffrey Karnes Vidit Sharma Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy Cancer Medicine biochemical recurrence prostate cancer salvage radiation therapy |
| title | Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy |
| title_full | Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy |
| title_fullStr | Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy |
| title_full_unstemmed | Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy |
| title_short | Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy |
| title_sort | understanding the impact of salvage radiation on the long term natural history of biochemically recurrent prostate cancer after radical prostatectomy |
| topic | biochemical recurrence prostate cancer salvage radiation therapy |
| url | https://doi.org/10.1002/cam4.70988 |
| work_keys_str_mv | AT spyridonpbasourakos understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT stephenaboorjian understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT phillipjschulte understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT granthenning understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT jamietobyrne understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT matthewktollefson understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT igorfrank understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT abhinavkhanna understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT ryanmphillips understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT bradleyjstish understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT rjeffreykarnes understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy AT viditsharma understandingtheimpactofsalvageradiationonthelongtermnaturalhistoryofbiochemicallyrecurrentprostatecancerafterradicalprostatectomy |